Table 2.
Advantages and disadvantages of different platforms for vaccine development.
| Platform | Advantages | Disadvantages |
|---|---|---|
| Attenuated pathogen | Produces humoral and cellular response with a single dose. | Safety problems in immunosuppressed people. Strains are difficult to obtain. |
| Dead/inactivated pathogen |
Safe due to the nature of its composition. Very easy to transport and store. |
Large amounts of the pathogen. Possible effects on the immunogenicity of the antigen |
| Protein subunits | Safe during production and for immunosuppressed people. | Decrease in APC * capacity due to particle size. Limited production due to product scalability. |
| Polysaccharides | Alternative against bacterias with abundant polysaccharide antigens. | There is only IgM production. Low memory immunity. Low efficiency in children. |
| Viral particles | Combines the efficacy of live and subunit vaccines. High scalability production. |
Particle assembly is a complex process. |
| Viral Vectors | It can induce a humoral and cellular response. Safe. |
Pre-existing immunity is used against the vector. It needs low temperatures to store. |
| Nucleic acid | Scalability. Rapid design and development. Very secure. Induces humoral and cellular responses. |
Its storage and handling are delicate. |